Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.
Recent Posts
Reflecting on Mental Health Awareness Month
By Andrew Powaleny | May 4, 2021
As communities around the world continue to grapple with the impact of COVID-19, the importance of furthering our understanding of the impact on our mental health is undeniable.
Read More
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging
By Andrew Powaleny | April 29, 2021
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened...
Read More
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
By Andrew Powaleny | April 12, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...
Read More
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
By Andrew Powaleny | March 8, 2021
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress
Read More
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
By Andrew Powaleny | January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...
Read More
ICYMI: Cancer death rate continues decline due to advances in treatment
By Andrew Powaleny | January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...
Read More
Report: More than 1,300 medicines and vaccines in development to help fight cancer
By Andrew Powaleny | December 15, 2020
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for...
Read More
Leading researchers to spotlight the critical role of biopharmaceutical R&D
By Andrew Powaleny | October 1, 2020
Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world.
Read More
Summer reading in the age of COVID-19
By Andrew Powaleny | August 21, 2020
As the summer of 2020 starts to creep to a close, America’s biopharmaceutical research companies are working around the clock to identify new treatments to reduce COVID-19 infection and vaccines,...
Read More
The patient perspective navigating COVID-19
By Andrew Powaleny | August 11, 2020
As PhRMA members work around the clock to combat COVID-19, the pandemic has had a tremendous impact around the globe. But for those patients who are currently impacted by a health care condition,...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
